Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Rhea-AI Summary

Compugen (CGEN) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before U.S. markets open. The clinical-stage cancer immunotherapy company will host a conference call and webcast at 8:30 am ET, where management will review financial results and provide a corporate update.

Investors can access the conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. A live webcast will be available through Compugen's website, with a replay accessible afterward.

HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.  Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.

Following the live webcast, a replay will be available on the Company's website.

About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2024-financial-results-on-tuesday-march-4-2025-302378746.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) release its Q4 and full year 2024 earnings?

Compugen will release its Q4 and full year 2024 financial results on Tuesday, March 4, 2025, before U.S. markets open.

What time is Compugen's (CGEN) Q4 2024 earnings call?

Compugen's Q4 2024 earnings conference call and webcast will take place at 8:30 am ET on March 4, 2025.

How can investors access Compugen's (CGEN) Q4 2024 earnings call?

Investors can access the call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally, or via webcast through Compugen's website.

Will there be a replay available for Compugen's (CGEN) Q4 2024 earnings call?

Yes, a replay of the webcast will be available on Compugen's website following the live presentation.